Finanzen von Onkure Therapeutics Inc (OKUR)OKUROnkure Therapeutics Inc

Evaluating the bottom line, Onkure Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -46.91%, provide a clear picture of how effectively OKUR converts its operational activities into shareholder value.

In the context of the broader market, OKUR competes directly with industry leaders such as NRXP and TNYA. With a market capitalization of $144.17M, it holds a significant position in the sector. When comparing efficiency, OKUR's gross margin of N/A stands against NRXP's 35.02% and TNYA's 100.00%. Such benchmarking helps identify whether Onkure Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has consistently reported negative net income, with the latest figures showing a net income of -15,157,000 in Q1 2026 and an EPS of -1.11, indicating ongoing financial challenges.